A Pancytopenic Patient With a Dry Tap
A 70-year-old man presents with fatigue, 8 kg weight loss, and early satiety. Examination shows marked splenomegaly 12 cm below the costal margin and no lymphadenopathy. Complete blood count: hemoglobin 9.2 g/dL, MCV 88 fL, platelets 62,000/µL, WBC 2,400/µL with 40% neutrophils, 50% lymphocytes, 8% monocytes, and 2% blasts. LDH is 480 U/L, haptoglobin is low, and the direct antiglobulin test is negative. A bone marrow aspirate is a dry tap; the trephine biopsy is hypercellular with fibrosis and clusters of atypical megakaryocytes. Flow cytometry of peripheral blood shows a population of CD34-positive, CD117-positive blasts comprising 2% of events.
1. Construct a differential diagnosis for splenomegaly with pancytopenia, dry tap, and marrow fibrosis, and explain how to prioritize it.
Read the worked answer
The differential includes primary myelofibrosis, myelodysplastic syndrome with fibrosis, acute megakaryoblastic leukemia, hairy cell leukemia, metastatic carcinoma, lymphoma with marrow involvement, and chronic myeloid leukemia. A dry tap with fibrosis and atypical megakaryocyte clusters in an older adult with massive splenomegaly strongly favors a myeloproliferative neoplasm, especially primary myelofibrosis. Hairy cell leukemia usually produces a dry tap and splenomegaly but would show monocytopenia and characteristic cells. Metastatic carcinoma and lymphoma should be excluded by morphology and immunohistochemistry. Prioritization should combine the trephine morphology, reticulin stain, peripheral blood findings, and molecular testing rather than relying on the aspirate.
2. What molecular and immunohistochemical tests would you order on the trephine biopsy, and how would you interpret them?
Read the worked answer
Order JAK2 V617F, JAK2 exon 12, CALR, and MPL mutation testing; immunohistochemistry for CD34, CD117, CD61 or factor VIII to highlight megakaryocytes, and a reticulin stain for fibrosis grade. JAK2 V617F or CALR mutation supports a myeloproliferative neoplasm; CALR and MPL mutations are mutually exclusive with JAK2 in most cases. Triple-negative status does not exclude myelofibrosis but raises consideration of other diagnoses. CD34 highlights blasts and vessels; increased CD34-positive blasts would raise concern for accelerated phase or acute transformation. The judgment is to integrate morphology, fibrosis grade, and mutation status into a WHO-defined diagnosis rather than treating any single result as definitive.
3. The patient is JAK2 V617F positive with grade 2 reticulin fibrosis and 2% blasts. How do these findings affect prognosis and management, and what is the role of the osteopathic principle of the body's self-regulatory capacity here?
Read the worked answer
JAK2 V617F positivity with grade 2 fibrosis and 2% blasts is consistent with primary myelofibrosis; prognosis is influenced by age, constitutional symptoms, blast percentage, hemoglobin, platelet count, and karyotype. Management is risk-adapted: low-risk patients may be observed, while intermediate- or high-risk patients may receive JAK inhibitors for splenomegaly and symptoms, and allogeneic transplant is considered in selected high-risk patients. The osteopathic principle of self-regulatory capacity supports attention to nutrition, activity, sleep, and symptom burden as adjuncts, but it does not replace molecularly guided therapy; the pathologist's role is to provide an accurate diagnosis and prognostic information so the clinician can support the patient's overall function alongside disease-directed treatment.